New hope for advanced stomach cancer: drug combo plus radiation shows promise
NCT ID NCT07490990
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study looks at a new treatment for people with a specific type of advanced stomach cancer (HER2-positive) that has stopped responding to standard therapies. It combines a targeted drug (disitamab vedotin) with immunotherapy and a special type of radiation. The goal is to see if this combination can help control the cancer longer and improve survival. About 30 people will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can a smart drug home in on Hard-to-Treat cancers?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?